Ex­e­Vir dos­es first pa­tients with lla­ma-de­rived an­ti-Covid an­ti­body

A lit­tle over five months af­ter pulling in a $50 mil­lion Se­ries A, Ex­e­Vir is ready to take the next step with its lla­ma-de­rived Covid-19 an­ti­bod­ies.

The Bel­gium-based biotech is of­fi­cial­ly launch­ing a Phase I study in healthy vol­un­teers for the lla­ma an­ti­body pro­gram, known as XVR011, an­nounc­ing the dos­ing of its first pa­tients Wednes­day morn­ing. Look­ing at the safe­ty pro­file and phar­ma­co­ki­net­ics of the can­di­date, the study will ex­am­ine three as­cend­ing dos­es of an IV for­mu­la­tion in a ran­dom­ized and dou­ble-blind­ed set­ting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER